Skip to main content
Premium Trial:

Request an Annual Quote

Novacyt to Get CE Mark for SARS-CoV-2 Variant Test

This article has been updated to note that Novacyt has not yet received the CE mark for the test but expects it will later this week.

NEW YORK — Novacyt said on Wednesday that it will receive the CE mark for SNPsig VariPlex, a PCR-based test designed to detect multiple SARS-CoV-2 variants of concern, this week.

According to the French diagnostics firm, the genotyping test detects four SARS-CoV-2 variants — first identified in the UK, South Africa, Brazil, and California, respectively — and two biologically significant mutations, all of which are now prevalent globally.

Novacyt said the test can be deployed in point-of-care settings and provides results in under two hours when used with its q32 instruments or by a lab using an open platform instrument capable of detection across at least four fluorescent channels.

Novacyt said it is making a research-use-only version of the test available for epidemiological applications and that it intends to pursue emergency use authorizations for it in various countries.

Earlier this year, Novacyt received CE marking for a next-generation high-throughput PCR test for COVID-19. The company also recently received CE marking for a test that can differentiate SARS-CoV-2 from flu and other respiratory infections.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.